GlassScriptPhysician profile
Daniel Wood
NPI 1811573769
$1,319.29
in general payments reported to CMS, 2019-2025
16 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.93 · 2022: $108 · 2023: $363 · 2024: $557 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,157.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $247.49 | 2024 | |
| Emd Serono, INC. | $207.17 | 2023-2025 | Mavenclad |
| Jazz Pharmaceuticals INC. | $140.22 | 2023-2024 | Epidiolex |
| Takeda Pharmaceuticals U.S.A., INC. | $116.64 | 2022-2025 | Hyqvia |
| Alexion Pharmaceuticals, INC. | $97.42 | 2023-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $79.09 | 2024-2025 | Wainua, Andexxa |
| Pfizer INC. | $78.45 | 2025 | |
| Genzyme Corporation | $74.32 | 2021-2022 | |
| Averitas Pharma INC. | $65.89 | 2023-2024 | Qutenza |
| Ucb, INC. | $58.97 | 2023-2024 | Briviact |
| Genentech USA, INC. | $50.05 | 2023-2025 | Enspryng, Ocrevus |
| Tg Therapeutics, INC. | $27.27 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.18 | 2022 | |
| Sk Life Science, INC. | $18.15 | 2025 | |
| Horizon Therapeutics Plc | $15.90 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15.08 | 2023 | Botox |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.